Analysts Expect CymaBay Therapeutics Inc (CBAY) Will Announce Earnings of -$0.27 Per Share

Equities research analysts forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will announce earnings of ($0.27) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.28). CymaBay Therapeutics reported earnings of ($0.29) per share during the same quarter last year, which suggests a positive year over year growth rate of 6.9%. The business is scheduled to announce its next quarterly earnings report on Wednesday, May 10th.

On average, analysts expect that CymaBay Therapeutics will report full year earnings of ($0.86) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.59). For the next financial year, analysts anticipate that the firm will report earnings of ($0.98) per share, with EPS estimates ranging from ($1.31) to ($0.68). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.02.

A number of analysts recently commented on CBAY shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target (up from $6.00) on shares of CymaBay Therapeutics in a research report on Monday, March 27th. Zacks Investment Research downgraded CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 3rd. Finally, Piper Jaffray Companies increased their price target on CymaBay Therapeutics from $5.00 to $6.50 and gave the company an “overweight” rating in a research report on Friday, March 24th.

A hedge fund recently bought a new stake in CymaBay Therapeutics stock. J. Goldman & Co LP purchased a new position in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 330,207 shares of the biopharmaceutical company’s stock, valued at approximately $571,000. J. Goldman & Co LP owned 1.41% of CymaBay Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 27.88% of the company’s stock.

WARNING: This piece of content was first reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at

Shares of CymaBay Therapeutics (NASDAQ:CBAY) traded down 0.47% during trading on Thursday, reaching $4.22. The company’s stock had a trading volume of 232,001 shares. The stock’s market cap is $121.33 million. CymaBay Therapeutics has a 52-week low of $1.15 and a 52-week high of $4.44. The stock has a 50-day moving average of $3.88 and a 200-day moving average of $2.41.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

5 Day Chart for NASDAQ:CBAY

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for CymaBay Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *